| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 366 | 2024 | 11083 | 13.210 |
Why?
|
| Androgen Antagonists | 86 | 2024 | 1411 | 6.430 |
Why?
|
| Prostate-Specific Antigen | 127 | 2024 | 2464 | 6.350 |
Why?
|
| Antineoplastic Agents, Hormonal | 53 | 2021 | 1534 | 3.940 |
Why?
|
| Neoplasms, Hormone-Dependent | 29 | 2016 | 409 | 3.740 |
Why?
|
| Tissue Extracts | 18 | 2020 | 139 | 3.180 |
Why?
|
| Receptors, Androgen | 42 | 2022 | 1088 | 3.140 |
Why?
|
| Cancer Vaccines | 20 | 2020 | 1044 | 2.980 |
Why?
|
| Kallikreins | 11 | 2021 | 220 | 2.190 |
Why?
|
| Taxoids | 26 | 2022 | 665 | 1.960 |
Why?
|
| Gene Expression Regulation, Neoplastic | 36 | 2022 | 8611 | 1.860 |
Why?
|
| Adenocarcinoma | 42 | 2017 | 6364 | 1.850 |
Why?
|
| Organic Anion Transporters | 6 | 2024 | 101 | 1.830 |
Why?
|
| Androgens | 32 | 2024 | 1279 | 1.780 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 51 | 2021 | 11868 | 1.720 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 3 | 2020 | 31 | 1.510 |
Why?
|
| Antineoplastic Agents | 60 | 2020 | 13648 | 1.500 |
Why?
|
| Prostatectomy | 39 | 2019 | 1782 | 1.500 |
Why?
|
| Male | 466 | 2024 | 363698 | 1.470 |
Why?
|
| Bone Neoplasms | 22 | 2020 | 2567 | 1.440 |
Why?
|
| Neoplasm Metastasis | 46 | 2024 | 4893 | 1.390 |
Why?
|
| Immunotherapy | 16 | 2016 | 4752 | 1.350 |
Why?
|
| Phenylthiohydantoin | 9 | 2020 | 206 | 1.310 |
Why?
|
| Orchiectomy | 19 | 2020 | 460 | 1.180 |
Why?
|
| RNA, Neoplasm | 5 | 2019 | 745 | 1.090 |
Why?
|
| Drug Resistance, Neoplasm | 34 | 2021 | 5337 | 1.050 |
Why?
|
| Gonadotropin-Releasing Hormone | 18 | 2017 | 1133 | 1.050 |
Why?
|
| Nitriles | 19 | 2020 | 982 | 0.990 |
Why?
|
| Neoplasm Recurrence, Local | 28 | 2020 | 9373 | 0.990 |
Why?
|
| Aged | 250 | 2024 | 171117 | 0.980 |
Why?
|
| Humans | 500 | 2024 | 765968 | 0.980 |
Why?
|
| Chromosomes, Human, Y | 2 | 2024 | 163 | 0.970 |
Why?
|
| MicroRNAs | 10 | 2019 | 3785 | 0.960 |
Why?
|
| Prognosis | 75 | 2022 | 29922 | 0.940 |
Why?
|
| Flutamide | 10 | 2012 | 96 | 0.940 |
Why?
|
| Chromosome Painting | 1 | 2024 | 26 | 0.920 |
Why?
|
| Testicular Neoplasms | 18 | 2012 | 786 | 0.890 |
Why?
|
| Selenium | 6 | 2016 | 419 | 0.880 |
Why?
|
| Testosterone | 21 | 2021 | 2494 | 0.870 |
Why?
|
| Middle Aged | 225 | 2024 | 223009 | 0.830 |
Why?
|
| Polymorphism, Single Nucleotide | 22 | 2018 | 16047 | 0.820 |
Why?
|
| Neoplasm Staging | 62 | 2021 | 11206 | 0.810 |
Why?
|
| Prednisone | 7 | 2021 | 1565 | 0.800 |
Why?
|
| Neoplasm Invasiveness | 12 | 2019 | 3602 | 0.780 |
Why?
|
| Survival Rate | 40 | 2024 | 12795 | 0.770 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2024 | 3251 | 0.770 |
Why?
|
| Oncogene Proteins, Fusion | 8 | 2022 | 1608 | 0.770 |
Why?
|
| Aged, 80 and over | 107 | 2021 | 59489 | 0.750 |
Why?
|
| Acupuncture, Ear | 1 | 2021 | 13 | 0.740 |
Why?
|
| Androstenes | 9 | 2021 | 178 | 0.740 |
Why?
|
| Urologic Neoplasms | 6 | 2015 | 310 | 0.740 |
Why?
|
| DNA, Neoplasm | 10 | 2019 | 1742 | 0.740 |
Why?
|
| Prostate | 23 | 2019 | 1755 | 0.730 |
Why?
|
| Cell Line, Tumor | 31 | 2022 | 17075 | 0.730 |
Why?
|
| Electroacupuncture | 1 | 2021 | 59 | 0.720 |
Why?
|
| Antineoplastic Agents, Phytogenic | 8 | 2009 | 616 | 0.710 |
Why?
|
| Polymorphism, Genetic | 20 | 2012 | 4247 | 0.710 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2019 | 891 | 0.690 |
Why?
|
| Leuprolide | 10 | 2018 | 312 | 0.690 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2021 | 147 | 0.670 |
Why?
|
| Trinucleotide Repeats | 8 | 2014 | 258 | 0.670 |
Why?
|
| Mitoxantrone | 6 | 2006 | 148 | 0.670 |
Why?
|
| Estramustine | 7 | 2013 | 35 | 0.650 |
Why?
|
| BRCA2 Protein | 4 | 2020 | 800 | 0.650 |
Why?
|
| Finasteride | 5 | 2004 | 86 | 0.650 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2022 | 2878 | 0.640 |
Why?
|
| Histone Demethylases | 3 | 2022 | 328 | 0.630 |
Why?
|
| Disease Progression | 48 | 2020 | 13632 | 0.630 |
Why?
|
| Thiazolidinediones | 4 | 2004 | 459 | 0.630 |
Why?
|
| Gene Silencing | 5 | 2020 | 1505 | 0.630 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2020 | 173 | 0.620 |
Why?
|
| Anilides | 10 | 2015 | 415 | 0.610 |
Why?
|
| Serine Endopeptidases | 4 | 2020 | 1024 | 0.610 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 499 | 0.600 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 4 | 2004 | 852 | 0.600 |
Why?
|
| Proportional Hazards Models | 38 | 2023 | 12509 | 0.600 |
Why?
|
| src-Family Kinases | 1 | 2020 | 538 | 0.590 |
Why?
|
| Kaplan-Meier Estimate | 23 | 2020 | 6499 | 0.570 |
Why?
|
| Survival Analysis | 32 | 2018 | 10070 | 0.560 |
Why?
|
| Disease-Free Survival | 23 | 2023 | 6832 | 0.560 |
Why?
|
| Urinary Bladder Neoplasms | 13 | 2014 | 2176 | 0.560 |
Why?
|
| PTEN Phosphohydrolase | 11 | 2020 | 1119 | 0.550 |
Why?
|
| DNA Repair | 6 | 2022 | 2048 | 0.550 |
Why?
|
| Combined Modality Therapy | 28 | 2019 | 8529 | 0.550 |
Why?
|
| Oncology Service, Hospital | 1 | 2017 | 55 | 0.540 |
Why?
|
| Superoxide Dismutase | 5 | 2016 | 593 | 0.540 |
Why?
|
| Genetic Association Studies | 7 | 2018 | 2741 | 0.540 |
Why?
|
| Carboplatin | 5 | 2017 | 789 | 0.540 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 752 | 0.520 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2021 | 3608 | 0.520 |
Why?
|
| Benzamides | 10 | 2020 | 1377 | 0.520 |
Why?
|
| Neoadjuvant Therapy | 13 | 2017 | 2895 | 0.510 |
Why?
|
| Biological Transport | 3 | 2017 | 2081 | 0.500 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2019 | 1061 | 0.490 |
Why?
|
| Cell Proliferation | 12 | 2021 | 10429 | 0.490 |
Why?
|
| Genetic Predisposition to Disease | 30 | 2020 | 18071 | 0.490 |
Why?
|
| Treatment Outcome | 85 | 2021 | 65188 | 0.490 |
Why?
|
| Biological Therapy | 1 | 2016 | 140 | 0.480 |
Why?
|
| Ketoconazole | 10 | 2014 | 93 | 0.480 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 7 | 2016 | 99 | 0.480 |
Why?
|
| Genotype | 30 | 2024 | 13024 | 0.470 |
Why?
|
| Follow-Up Studies | 50 | 2024 | 39193 | 0.470 |
Why?
|
| Chromosomes, Human, Pair 8 | 5 | 2009 | 451 | 0.470 |
Why?
|
| Cohort Studies | 49 | 2024 | 41649 | 0.460 |
Why?
|
| Tosyl Compounds | 8 | 2015 | 115 | 0.460 |
Why?
|
| Radiotherapy, Conformal | 7 | 2009 | 533 | 0.450 |
Why?
|
| Urothelium | 3 | 2014 | 272 | 0.440 |
Why?
|
| Carcinoma, Transitional Cell | 8 | 2015 | 790 | 0.440 |
Why?
|
| rab1 GTP-Binding Proteins | 1 | 2013 | 6 | 0.440 |
Why?
|
| Genetic Variation | 7 | 2020 | 6610 | 0.440 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 2034 | 0.430 |
Why?
|
| Risk Factors | 72 | 2024 | 74840 | 0.430 |
Why?
|
| Dehydroepiandrosterone Sulfate | 4 | 2015 | 238 | 0.430 |
Why?
|
| Chromans | 3 | 2002 | 116 | 0.410 |
Why?
|
| 5-alpha Reductase Inhibitors | 4 | 2018 | 114 | 0.410 |
Why?
|
| Watchful Waiting | 4 | 2023 | 493 | 0.410 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2011 | 558 | 0.400 |
Why?
|
| Enzyme Inhibitors | 6 | 2004 | 3715 | 0.400 |
Why?
|
| Endpoint Determination | 5 | 2020 | 591 | 0.400 |
Why?
|
| Gonadal Steroid Hormones | 4 | 2011 | 705 | 0.400 |
Why?
|
| Chemokine CCL2 | 2 | 2014 | 602 | 0.390 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2015 | 506 | 0.390 |
Why?
|
| Carcinoma | 4 | 2014 | 2312 | 0.390 |
Why?
|
| RNA Interference | 8 | 2020 | 2832 | 0.390 |
Why?
|
| Estradiol Dehydrogenases | 1 | 2011 | 16 | 0.390 |
Why?
|
| Drugs, Chinese Herbal | 3 | 2004 | 142 | 0.380 |
Why?
|
| Erectile Dysfunction | 7 | 2014 | 437 | 0.380 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2011 | 28 | 0.370 |
Why?
|
| Endostatins | 2 | 2009 | 167 | 0.370 |
Why?
|
| Seminoma | 4 | 2006 | 134 | 0.370 |
Why?
|
| Paclitaxel | 4 | 2006 | 1728 | 0.370 |
Why?
|
| Clinical Trials as Topic | 21 | 2021 | 8041 | 0.370 |
Why?
|
| Survivors | 5 | 2020 | 2372 | 0.360 |
Why?
|
| Promoter Regions, Genetic | 5 | 2019 | 5786 | 0.360 |
Why?
|
| Cisplatin | 12 | 2014 | 1658 | 0.360 |
Why?
|
| Prostatic Hyperplasia | 3 | 2018 | 515 | 0.350 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2012 | 457 | 0.340 |
Why?
|
| Salvage Therapy | 7 | 2018 | 1272 | 0.340 |
Why?
|
| Transcriptional Activation | 5 | 2022 | 1744 | 0.340 |
Why?
|
| Chemotherapy, Adjuvant | 20 | 2018 | 3537 | 0.340 |
Why?
|
| Poxviridae | 1 | 2010 | 37 | 0.340 |
Why?
|
| Risk Assessment | 29 | 2024 | 24282 | 0.340 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2014 | 1365 | 0.330 |
Why?
|
| Prospective Studies | 50 | 2024 | 54802 | 0.330 |
Why?
|
| Cholesterol | 1 | 2019 | 2898 | 0.330 |
Why?
|
| Nucleoside Deaminases | 7 | 1988 | 58 | 0.330 |
Why?
|
| Kidney Neoplasms | 10 | 2015 | 4274 | 0.330 |
Why?
|
| Nanoparticles | 7 | 2018 | 1964 | 0.330 |
Why?
|
| Biological Products | 1 | 2019 | 942 | 0.320 |
Why?
|
| Radiosurgery | 1 | 2019 | 1328 | 0.320 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2016 | 4562 | 0.320 |
Why?
|
| RNA, Messenger | 12 | 2018 | 12768 | 0.320 |
Why?
|
| Minor Histocompatibility Antigens | 4 | 2022 | 303 | 0.320 |
Why?
|
| Gene Expression Profiling | 15 | 2020 | 9525 | 0.320 |
Why?
|
| Neoplasms | 17 | 2021 | 22340 | 0.310 |
Why?
|
| Mutation | 23 | 2024 | 30198 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 19 | 2024 | 10383 | 0.310 |
Why?
|
| Neoplastic Cells, Circulating | 5 | 2019 | 950 | 0.310 |
Why?
|
| Time Factors | 35 | 2021 | 40065 | 0.310 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 5 | 2006 | 480 | 0.310 |
Why?
|
| Vaccines, DNA | 1 | 2009 | 279 | 0.300 |
Why?
|
| Adenosine Deaminase | 10 | 1989 | 251 | 0.300 |
Why?
|
| DNA Copy Number Variations | 5 | 2020 | 2045 | 0.300 |
Why?
|
| Adult | 96 | 2024 | 223044 | 0.300 |
Why?
|
| Hemoglobins | 6 | 2013 | 1530 | 0.290 |
Why?
|
| Plant Extracts | 2 | 2002 | 496 | 0.290 |
Why?
|
| Transfection | 11 | 2018 | 5743 | 0.280 |
Why?
|
| Germ-Line Mutation | 8 | 2017 | 1884 | 0.280 |
Why?
|
| Brachytherapy | 8 | 2018 | 1222 | 0.280 |
Why?
|
| Multivariate Analysis | 18 | 2016 | 12056 | 0.280 |
Why?
|
| Radiopharmaceuticals | 3 | 2014 | 2699 | 0.270 |
Why?
|
| Germinoma | 4 | 2003 | 124 | 0.270 |
Why?
|
| Double-Blind Method | 12 | 2019 | 12437 | 0.270 |
Why?
|
| Radium | 3 | 2017 | 70 | 0.270 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 1132 | 0.270 |
Why?
|
| Retrospective Studies | 49 | 2022 | 81514 | 0.260 |
Why?
|
| Drug Therapy, Combination | 10 | 2020 | 6309 | 0.260 |
Why?
|
| Drug Synergism | 3 | 2020 | 1749 | 0.260 |
Why?
|
| Drug Administration Schedule | 12 | 2018 | 4850 | 0.260 |
Why?
|
| Goserelin | 4 | 2013 | 126 | 0.260 |
Why?
|
| Vinblastine | 6 | 2014 | 483 | 0.260 |
Why?
|
| Case-Control Studies | 30 | 2016 | 22223 | 0.250 |
Why?
|
| Vitamin D | 2 | 2019 | 3272 | 0.250 |
Why?
|
| Carcinoma, Renal Cell | 8 | 2015 | 3181 | 0.250 |
Why?
|
| DNA Methylation | 2 | 2019 | 4424 | 0.250 |
Why?
|
| Histone Code | 2 | 2018 | 159 | 0.250 |
Why?
|
| Tissue Array Analysis | 4 | 2021 | 545 | 0.250 |
Why?
|
| Acupuncture Therapy | 2 | 2020 | 466 | 0.250 |
Why?
|
| Neoplasm Proteins | 7 | 2020 | 3596 | 0.250 |
Why?
|
| Thiazoles | 3 | 2002 | 1529 | 0.250 |
Why?
|
| Nomograms | 1 | 2007 | 235 | 0.250 |
Why?
|
| Cause of Death | 10 | 2017 | 3708 | 0.250 |
Why?
|
| Genes, BRCA2 | 2 | 2019 | 588 | 0.240 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2012 | 2056 | 0.240 |
Why?
|
| Glutamate Carboxypeptidase II | 3 | 2015 | 90 | 0.240 |
Why?
|
| Predictive Value of Tests | 19 | 2020 | 15398 | 0.240 |
Why?
|
| Suicidal Ideation | 2 | 2014 | 1461 | 0.240 |
Why?
|
| Transcription Factors | 7 | 2018 | 12131 | 0.240 |
Why?
|
| Immunohistochemistry | 16 | 2019 | 11022 | 0.230 |
Why?
|
| Signal Transduction | 17 | 2021 | 23601 | 0.230 |
Why?
|
| Chromogranins | 1 | 2005 | 161 | 0.230 |
Why?
|
| Mice, SCID | 3 | 2019 | 2630 | 0.230 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2006 | 268 | 0.230 |
Why?
|
| Genes, Neoplasm | 1 | 2006 | 370 | 0.230 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 3 | 2004 | 75 | 0.230 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 1837 | 0.230 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 318 | 0.230 |
Why?
|
| Doxorubicin | 5 | 2014 | 2230 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 8 | 2024 | 3655 | 0.220 |
Why?
|
| Azasteroids | 4 | 2014 | 37 | 0.220 |
Why?
|
| Urinary Incontinence | 3 | 2003 | 491 | 0.220 |
Why?
|
| Teratoma | 4 | 2012 | 401 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 1892 | 0.220 |
Why?
|
| Estrogen Receptor beta | 3 | 2010 | 171 | 0.220 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2015 | 2942 | 0.220 |
Why?
|
| Mice, Nude | 3 | 2020 | 3618 | 0.210 |
Why?
|
| Genetic Vectors | 19 | 2010 | 3404 | 0.210 |
Why?
|
| Biopsy | 7 | 2023 | 6763 | 0.210 |
Why?
|
| Dihydrotestosterone | 6 | 2013 | 193 | 0.210 |
Why?
|
| Retroviridae | 13 | 1990 | 847 | 0.210 |
Why?
|
| BRCA1 Protein | 4 | 2020 | 1153 | 0.210 |
Why?
|
| Oncogenes | 2 | 2020 | 1235 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2020 | 561 | 0.210 |
Why?
|
| Ribonucleases | 1 | 2003 | 265 | 0.210 |
Why?
|
| Age Factors | 15 | 2022 | 18380 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3100 | 0.200 |
Why?
|
| Life Expectancy | 3 | 2010 | 1247 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3223 | 0.200 |
Why?
|
| Androgen Receptor Antagonists | 4 | 2013 | 123 | 0.200 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2022 | 76 | 0.190 |
Why?
|
| Phenotype | 13 | 2020 | 16721 | 0.190 |
Why?
|
| Aptamers, Nucleotide | 3 | 2008 | 163 | 0.190 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2004 | 393 | 0.190 |
Why?
|
| Comorbidity | 10 | 2018 | 10563 | 0.190 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 4 | 2022 | 166 | 0.190 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2021 | 540 | 0.190 |
Why?
|
| Quality of Life | 14 | 2024 | 13462 | 0.190 |
Why?
|
| Selenoproteins | 2 | 2016 | 216 | 0.190 |
Why?
|
| Specimen Handling | 1 | 2006 | 704 | 0.190 |
Why?
|
| Sulfonamides | 2 | 2014 | 1984 | 0.190 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2010 | 3797 | 0.190 |
Why?
|
| Confidence Intervals | 6 | 2019 | 2910 | 0.180 |
Why?
|
| Risk | 11 | 2014 | 9591 | 0.180 |
Why?
|
| United States | 32 | 2024 | 72903 | 0.180 |
Why?
|
| Neoplasms, Bone Tissue | 1 | 2020 | 7 | 0.180 |
Why?
|
| Animals | 38 | 2021 | 168764 | 0.180 |
Why?
|
| New Zealand | 1 | 2021 | 359 | 0.180 |
Why?
|
| Gabexate | 1 | 2020 | 12 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2018 | 2505 | 0.170 |
Why?
|
| Biopsy, Needle | 3 | 2019 | 1628 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 3 | 2010 | 578 | 0.170 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2020 | 1090 | 0.170 |
Why?
|
| DNA Damage | 2 | 2022 | 2457 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 15 | 2011 | 6069 | 0.170 |
Why?
|
| Aspirin | 4 | 2018 | 3134 | 0.170 |
Why?
|
| Anticarcinogenic Agents | 2 | 2001 | 250 | 0.170 |
Why?
|
| Cancer Care Facilities | 3 | 2019 | 426 | 0.170 |
Why?
|
| Nanotechnology | 2 | 2016 | 703 | 0.170 |
Why?
|
| Drug Delivery Systems | 5 | 2013 | 2207 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 2822 | 0.160 |
Why?
|
| Chromosome Deletion | 2 | 2024 | 1385 | 0.160 |
Why?
|
| Diphosphonates | 4 | 2007 | 625 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2014 | 878 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2003 | 679 | 0.160 |
Why?
|
| Australia | 2 | 2021 | 1258 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 5 | 2020 | 6113 | 0.160 |
Why?
|
| Guanidines | 1 | 2020 | 194 | 0.160 |
Why?
|
| DNA Mutational Analysis | 7 | 2017 | 4108 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2016 | 3513 | 0.160 |
Why?
|
| SEER Program | 3 | 2019 | 1446 | 0.160 |
Why?
|
| Mice | 23 | 2021 | 81819 | 0.160 |
Why?
|
| Alleles | 12 | 2018 | 6897 | 0.160 |
Why?
|
| Esters | 1 | 2020 | 214 | 0.160 |
Why?
|
| Mass Screening | 7 | 2014 | 5446 | 0.160 |
Why?
|
| Regression Analysis | 6 | 2015 | 6322 | 0.160 |
Why?
|
| Peptide Hydrolases | 1 | 2021 | 608 | 0.150 |
Why?
|
| Aromatase Inhibitors | 1 | 2002 | 518 | 0.150 |
Why?
|
| Mediastinal Neoplasms | 3 | 2003 | 403 | 0.150 |
Why?
|
| Progesterone Reductase | 1 | 2018 | 14 | 0.150 |
Why?
|
| HLA-A2 Antigen | 1 | 2019 | 207 | 0.150 |
Why?
|
| Cholecalciferol | 1 | 2003 | 550 | 0.150 |
Why?
|
| Steroid Isomerases | 1 | 2018 | 19 | 0.150 |
Why?
|
| Forecasting | 5 | 2019 | 2936 | 0.150 |
Why?
|
| Computational Biology | 5 | 2020 | 3559 | 0.150 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2018 | 170 | 0.150 |
Why?
|
| Antigens, Surface | 4 | 2015 | 1617 | 0.150 |
Why?
|
| Glycolysis | 1 | 2022 | 838 | 0.150 |
Why?
|
| Aging | 2 | 2012 | 8731 | 0.150 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2000 | 218 | 0.150 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2013 | 412 | 0.150 |
Why?
|
| Lymph Node Excision | 7 | 2016 | 1259 | 0.150 |
Why?
|
| Gene Dosage | 3 | 2018 | 1216 | 0.150 |
Why?
|
| Epigenesis, Genetic | 5 | 2022 | 3819 | 0.150 |
Why?
|
| Organoids | 1 | 2024 | 739 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2022 | 2453 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 20659 | 0.140 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3946 | 0.140 |
Why?
|
| Treatment Failure | 5 | 2015 | 2652 | 0.140 |
Why?
|
| Genes, BRCA1 | 3 | 2010 | 750 | 0.140 |
Why?
|
| Chromosome Aberrations | 5 | 2019 | 1774 | 0.140 |
Why?
|
| Moloney murine leukemia virus | 7 | 1989 | 110 | 0.140 |
Why?
|
| Radionuclide Imaging | 4 | 2016 | 1978 | 0.140 |
Why?
|
| Genitalia, Male | 1 | 1997 | 87 | 0.140 |
Why?
|
| Trans-Activators | 4 | 2022 | 2850 | 0.140 |
Why?
|
| Hydrocortisone | 2 | 2009 | 1827 | 0.140 |
Why?
|
| Platinum | 2 | 2015 | 218 | 0.140 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2018 | 162 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 4 | 2019 | 9249 | 0.140 |
Why?
|
| Triazoles | 1 | 2002 | 897 | 0.140 |
Why?
|
| Glutathione Peroxidase | 2 | 2016 | 256 | 0.140 |
Why?
|
| Castration | 6 | 2012 | 149 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 1857 | 0.140 |
Why?
|
| Pyrazoles | 2 | 2008 | 2033 | 0.130 |
Why?
|
| Pain | 5 | 2023 | 5077 | 0.130 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2020 | 660 | 0.130 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 6 | 2004 | 780 | 0.130 |
Why?
|
| Interleukin-6 | 2 | 2013 | 3222 | 0.130 |
Why?
|
| Thioredoxin Reductase 2 | 1 | 2016 | 25 | 0.130 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2016 | 32 | 0.130 |
Why?
|
| Selenium-Binding Proteins | 1 | 2016 | 18 | 0.130 |
Why?
|
| Transcription, Genetic | 10 | 2014 | 7599 | 0.130 |
Why?
|
| Endonucleases | 2 | 2015 | 372 | 0.130 |
Why?
|
| Pain Perception | 1 | 2017 | 198 | 0.130 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 433 | 0.130 |
Why?
|
| Up-Regulation | 4 | 2020 | 4137 | 0.130 |
Why?
|
| Statistics as Topic | 4 | 2016 | 2352 | 0.120 |
Why?
|
| Androstadienes | 2 | 2014 | 347 | 0.120 |
Why?
|
| Glutamine | 1 | 1998 | 576 | 0.120 |
Why?
|
| Suramin | 3 | 2001 | 34 | 0.120 |
Why?
|
| Oncogene Proteins | 2 | 2012 | 710 | 0.120 |
Why?
|
| Infusions, Intravenous | 4 | 2020 | 2229 | 0.120 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 98 | 0.120 |
Why?
|
| Antigens, Neoplasm | 3 | 2015 | 2002 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 2268 | 0.120 |
Why?
|
| Databases, Genetic | 2 | 2020 | 1751 | 0.120 |
Why?
|
| Genomics | 4 | 2020 | 5929 | 0.120 |
Why?
|
| Protein Isoforms | 2 | 2016 | 1718 | 0.120 |
Why?
|
| Medical Oncology | 5 | 2020 | 2339 | 0.120 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 728 | 0.120 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 2014 | 33 | 0.120 |
Why?
|
| Hydroxyprostaglandin Dehydrogenases | 1 | 2014 | 31 | 0.120 |
Why?
|
| Liver Neoplasms | 2 | 2013 | 4353 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2008 | 1167 | 0.120 |
Why?
|
| Denmark | 1 | 2017 | 774 | 0.120 |
Why?
|
| Radioisotopes | 2 | 2013 | 495 | 0.120 |
Why?
|
| Haplotypes | 2 | 2011 | 2728 | 0.120 |
Why?
|
| Erythropoiesis | 1 | 2018 | 691 | 0.120 |
Why?
|
| Multienzyme Complexes | 1 | 2018 | 663 | 0.120 |
Why?
|
| Self Report | 3 | 2021 | 3770 | 0.120 |
Why?
|
| Tissue Kallikreins | 1 | 2014 | 14 | 0.120 |
Why?
|
| Mediator Complex Subunit 1 | 1 | 2014 | 31 | 0.110 |
Why?
|
| Registries | 8 | 2024 | 8297 | 0.110 |
Why?
|
| Body Composition | 2 | 2014 | 2439 | 0.110 |
Why?
|
| Incidence | 13 | 2019 | 21480 | 0.110 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2014 | 105 | 0.110 |
Why?
|
| Erythropoietin | 1 | 2018 | 716 | 0.110 |
Why?
|
| Prescription Fees | 1 | 2015 | 153 | 0.110 |
Why?
|
| Insurance Benefits | 1 | 2016 | 186 | 0.110 |
Why?
|
| Anoikis | 1 | 2014 | 49 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 995 | 0.110 |
Why?
|
| Endothelial Growth Factors | 3 | 2001 | 680 | 0.110 |
Why?
|
| Benchmarking | 1 | 2020 | 1052 | 0.110 |
Why?
|
| Binding, Competitive | 1 | 2015 | 1140 | 0.110 |
Why?
|
| Nanomedicine | 1 | 2016 | 286 | 0.110 |
Why?
|
| Consumer Health Information | 1 | 2016 | 215 | 0.110 |
Why?
|
| Lymphatic Metastasis | 9 | 2014 | 2887 | 0.110 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2014 | 109 | 0.110 |
Why?
|
| Phosphorylation | 3 | 2021 | 8278 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 1599 | 0.110 |
Why?
|
| Pyridines | 2 | 2015 | 2888 | 0.110 |
Why?
|
| Lymphokines | 3 | 2001 | 911 | 0.110 |
Why?
|
| Gene Expression | 7 | 2017 | 7584 | 0.110 |
Why?
|
| Reference Values | 3 | 2005 | 4908 | 0.110 |
Why?
|
| Hormones | 3 | 2005 | 863 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2013 | 125 | 0.100 |
Why?
|
| Protective Agents | 1 | 2014 | 151 | 0.100 |
Why?
|
| Introns | 1 | 2015 | 966 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 385 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 5696 | 0.100 |
Why?
|
| Probability | 3 | 2009 | 2475 | 0.100 |
Why?
|
| Patient Advocacy | 1 | 2015 | 361 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1084 | 0.100 |
Why?
|
| Patient Selection | 4 | 2019 | 4255 | 0.100 |
Why?
|
| Acid Phosphatase | 1 | 2012 | 139 | 0.100 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2012 | 335 | 0.100 |
Why?
|
| Apoptosis | 4 | 2020 | 9514 | 0.100 |
Why?
|
| Metabolome | 1 | 2019 | 1005 | 0.100 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2012 | 61 | 0.100 |
Why?
|
| Polymers | 3 | 2014 | 1621 | 0.100 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2012 | 93 | 0.100 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2012 | 44 | 0.100 |
Why?
|
| COS Cells | 1 | 2014 | 1136 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 1927 | 0.100 |
Why?
|
| Pyrrolidines | 2 | 2006 | 337 | 0.100 |
Why?
|
| Faculty, Medical | 1 | 2020 | 1219 | 0.100 |
Why?
|
| Alkaline Phosphatase | 2 | 2013 | 854 | 0.100 |
Why?
|
| Single-Cell Analysis | 2 | 2020 | 2535 | 0.100 |
Why?
|
| Pyrophosphatases | 1 | 2012 | 141 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 3110 | 0.100 |
Why?
|
| Mediator Complex | 1 | 2012 | 106 | 0.100 |
Why?
|
| Vitamin E | 1 | 2016 | 869 | 0.100 |
Why?
|
| Early Detection of Cancer | 4 | 2015 | 3236 | 0.100 |
Why?
|
| Gene Fusion | 2 | 2012 | 357 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 3432 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 4 | 2016 | 857 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2021 | 2880 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2015 | 1624 | 0.090 |
Why?
|
| Platinum Compounds | 1 | 2011 | 94 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 633 | 0.090 |
Why?
|
| Dioxoles | 1 | 2011 | 98 | 0.090 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2011 | 81 | 0.090 |
Why?
|
| Research Design | 4 | 2016 | 6209 | 0.090 |
Why?
|
| Endoribonucleases | 1 | 2013 | 229 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 4 | 2015 | 4772 | 0.090 |
Why?
|
| Prostatic Secretory Proteins | 1 | 2010 | 24 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 2844 | 0.090 |
Why?
|
| Sirolimus | 2 | 2015 | 1545 | 0.090 |
Why?
|
| Genome, Human | 3 | 2014 | 4448 | 0.090 |
Why?
|
| Diarrhea | 1 | 1998 | 1316 | 0.090 |
Why?
|
| Interleukin-8 | 1 | 2014 | 700 | 0.090 |
Why?
|
| Vasodilation | 1 | 2015 | 970 | 0.090 |
Why?
|
| Estrogens | 2 | 2008 | 1529 | 0.090 |
Why?
|
| Cysteine | 1 | 2015 | 898 | 0.090 |
Why?
|
| Listeria monocytogenes | 1 | 2012 | 244 | 0.090 |
Why?
|
| Cell Differentiation | 3 | 2011 | 11641 | 0.090 |
Why?
|
| Imidazoles | 2 | 2007 | 1162 | 0.090 |
Why?
|
| Nephrectomy | 4 | 2012 | 927 | 0.090 |
Why?
|
| Immunity, Humoral | 1 | 2015 | 605 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 1892 | 0.090 |
Why?
|
| Antigen-Presenting Cells | 2 | 2012 | 962 | 0.090 |
Why?
|
| Myocardial Infarction | 2 | 2011 | 11499 | 0.090 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2010 | 62 | 0.090 |
Why?
|
| Transformation, Genetic | 2 | 1987 | 194 | 0.090 |
Why?
|
| Reproducibility of Results | 7 | 2024 | 20124 | 0.090 |
Why?
|
| Androstenols | 1 | 2010 | 25 | 0.090 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2014 | 792 | 0.090 |
Why?
|
| Indium Radioisotopes | 1 | 2010 | 113 | 0.090 |
Why?
|
| Antioxidants | 2 | 2011 | 1670 | 0.090 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2010 | 150 | 0.090 |
Why?
|
| Progesterone | 1 | 2014 | 752 | 0.090 |
Why?
|
| Lung Neoplasms | 3 | 2013 | 13451 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 274 | 0.080 |
Why?
|
| Fluorescence Resonance Energy Transfer | 2 | 2014 | 416 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1999 | 1808 | 0.080 |
Why?
|
| Cystectomy | 1 | 2014 | 604 | 0.080 |
Why?
|
| T-Lymphocytes | 5 | 2012 | 10261 | 0.080 |
Why?
|
| Piperidines | 2 | 2011 | 1664 | 0.080 |
Why?
|
| Cell Cycle | 3 | 2017 | 2920 | 0.080 |
Why?
|
| Eosinophils | 1 | 2014 | 945 | 0.080 |
Why?
|
| Female | 36 | 2021 | 396112 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2019 | 10729 | 0.080 |
Why?
|
| Genetic Markers | 5 | 2010 | 2601 | 0.080 |
Why?
|
| Methotrexate | 5 | 2014 | 1722 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2011 | 2423 | 0.080 |
Why?
|
| Genome-Wide Association Study | 6 | 2015 | 12807 | 0.080 |
Why?
|
| Microdissection | 2 | 2006 | 152 | 0.080 |
Why?
|
| Glutathione Transferase | 2 | 2002 | 562 | 0.080 |
Why?
|
| Gene Frequency | 4 | 2015 | 3624 | 0.080 |
Why?
|
| Radiotherapy | 5 | 2010 | 1494 | 0.080 |
Why?
|
| Yttrium Radioisotopes | 1 | 2010 | 116 | 0.080 |
Why?
|
| Camptothecin | 1 | 2012 | 600 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2011 | 517 | 0.080 |
Why?
|
| Linkage Disequilibrium | 2 | 2010 | 1997 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2020 | 1539 | 0.080 |
Why?
|
| Drug Approval | 1 | 2016 | 818 | 0.080 |
Why?
|
| Receptors, Calcitriol | 1 | 2011 | 361 | 0.080 |
Why?
|
| Patient Preference | 1 | 2016 | 952 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 7425 | 0.080 |
Why?
|
| Algorithms | 4 | 2020 | 14071 | 0.080 |
Why?
|
| Bone Marrow | 6 | 2005 | 2921 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 381 | 0.080 |
Why?
|
| Retroperitoneal Space | 4 | 2003 | 173 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 360 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2014 | 3047 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2020 | 1880 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2012 | 3737 | 0.070 |
Why?
|
| Physical Examination | 1 | 2014 | 1266 | 0.070 |
Why?
|
| Disease Management | 1 | 2019 | 2535 | 0.070 |
Why?
|
| Genes, myc | 1 | 2009 | 393 | 0.070 |
Why?
|
| Artifacts | 2 | 2007 | 1893 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 2 | 2014 | 898 | 0.070 |
Why?
|
| Hormone Antagonists | 1 | 2008 | 108 | 0.070 |
Why?
|
| Dinucleotide Repeats | 1 | 2007 | 28 | 0.070 |
Why?
|
| Insulin | 1 | 2022 | 6599 | 0.070 |
Why?
|
| Pilot Projects | 6 | 2013 | 8733 | 0.070 |
Why?
|
| Genetic Testing | 2 | 2017 | 3595 | 0.070 |
Why?
|
| Glucuronosyltransferase | 1 | 2008 | 136 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2009 | 416 | 0.070 |
Why?
|
| Immunologic Deficiency Syndromes | 3 | 1988 | 548 | 0.070 |
Why?
|
| Chromatin | 2 | 2017 | 2980 | 0.070 |
Why?
|
| Smoking | 2 | 2005 | 9081 | 0.070 |
Why?
|
| Odds Ratio | 8 | 2017 | 9649 | 0.070 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 734 | 0.070 |
Why?
|
| Mifepristone | 1 | 2008 | 150 | 0.070 |
Why?
|
| Genetics, Population | 2 | 2010 | 943 | 0.070 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2010 | 456 | 0.070 |
Why?
|
| Gene Expression Regulation | 5 | 2020 | 11888 | 0.070 |
Why?
|
| Ferrosoferric Oxide | 1 | 2008 | 349 | 0.070 |
Why?
|
| Endothelium, Vascular | 3 | 2015 | 4427 | 0.070 |
Why?
|
| Drug Costs | 1 | 2015 | 1193 | 0.070 |
Why?
|
| Vaccines, Synthetic | 1 | 2010 | 621 | 0.070 |
Why?
|
| Saskatchewan | 2 | 2018 | 8 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 1066 | 0.070 |
Why?
|
| Genetic Engineering | 7 | 1988 | 933 | 0.070 |
Why?
|
| Radiography, Interventional | 1 | 2014 | 1129 | 0.070 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 798 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2000 | 4040 | 0.070 |
Why?
|
| Tumor Burden | 3 | 2019 | 1885 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 4 | 2017 | 1731 | 0.070 |
Why?
|
| Laparoscopy | 4 | 2003 | 2039 | 0.070 |
Why?
|
| Cell Line | 3 | 2017 | 15543 | 0.070 |
Why?
|
| Cells, Cultured | 7 | 2019 | 18973 | 0.070 |
Why?
|
| Body Mass Index | 4 | 2017 | 13039 | 0.070 |
Why?
|
| Decision Support Techniques | 3 | 2013 | 2003 | 0.070 |
Why?
|
| Electronic Health Records | 3 | 2022 | 4873 | 0.060 |
Why?
|
| Patient Participation | 1 | 2015 | 1455 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2010 | 4520 | 0.060 |
Why?
|
| Depression | 2 | 2017 | 8237 | 0.060 |
Why?
|
| Quantum Dots | 1 | 2007 | 168 | 0.060 |
Why?
|
| Recurrence | 5 | 2013 | 8501 | 0.060 |
Why?
|
| Imidazolidines | 1 | 2005 | 38 | 0.060 |
Why?
|
| beta Carotene | 2 | 2005 | 522 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 2024 | 0.060 |
Why?
|
| Pyrroles | 2 | 2009 | 1119 | 0.060 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2007 | 274 | 0.060 |
Why?
|
| Chromogranin A | 1 | 2005 | 49 | 0.060 |
Why?
|
| Kinetics | 3 | 2009 | 6274 | 0.060 |
Why?
|
| Immunoglobulin G | 3 | 2015 | 4528 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2022 | 3430 | 0.060 |
Why?
|
| Magnetics | 1 | 2008 | 585 | 0.060 |
Why?
|
| Immunoblotting | 3 | 2016 | 1644 | 0.060 |
Why?
|
| Immunization | 1 | 2010 | 1219 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2015 | 2631 | 0.060 |
Why?
|
| Quinazolines | 1 | 2011 | 1364 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 10 | 1990 | 3401 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 5370 | 0.060 |
Why?
|
| Lasers | 2 | 2006 | 951 | 0.060 |
Why?
|
| Ligands | 2 | 2003 | 3273 | 0.060 |
Why?
|
| Osteoporosis | 2 | 2007 | 1582 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 2056 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2008 | 1638 | 0.060 |
Why?
|
| Racemases and Epimerases | 1 | 2005 | 113 | 0.060 |
Why?
|
| Spirochaetales Infections | 1 | 1984 | 11 | 0.060 |
Why?
|
| Acetyltransferases | 1 | 2005 | 229 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2009 | 696 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 3421 | 0.060 |
Why?
|
| RNA | 2 | 2012 | 2717 | 0.060 |
Why?
|
| Diethylstilbestrol | 1 | 2004 | 84 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2010 | 708 | 0.060 |
Why?
|
| Logistic Models | 8 | 2017 | 13266 | 0.060 |
Why?
|
| Peptide Library | 1 | 2005 | 351 | 0.060 |
Why?
|
| Cell Survival | 5 | 2014 | 5747 | 0.060 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2012 | 507 | 0.060 |
Why?
|
| Polyethylene Glycols | 3 | 2018 | 1188 | 0.060 |
Why?
|
| DNA-Binding Proteins | 3 | 2015 | 9601 | 0.060 |
Why?
|
| Motivation | 1 | 2013 | 2018 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 7 | 1989 | 2729 | 0.050 |
Why?
|
| Health Care Costs | 2 | 2016 | 3242 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 976 | 0.050 |
Why?
|
| Lymphocyte Transfusion | 2 | 2002 | 236 | 0.050 |
Why?
|
| Skin Diseases, Infectious | 1 | 1984 | 73 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2013 | 1587 | 0.050 |
Why?
|
| Heart Diseases | 2 | 2015 | 2821 | 0.050 |
Why?
|
| Carrier Proteins | 2 | 2014 | 4913 | 0.050 |
Why?
|
| Osteoclasts | 1 | 2007 | 713 | 0.050 |
Why?
|
| Monocytes | 2 | 2010 | 2595 | 0.050 |
Why?
|
| Antibodies, Neoplasm | 2 | 2002 | 282 | 0.050 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2015 | 476 | 0.050 |
Why?
|
| Overweight | 2 | 2017 | 2444 | 0.050 |
Why?
|
| Obesity | 2 | 2017 | 13076 | 0.050 |
Why?
|
| Drug Contamination | 1 | 2004 | 152 | 0.050 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2003 | 80 | 0.050 |
Why?
|
| Genes, Viral | 4 | 1990 | 654 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 1652 | 0.050 |
Why?
|
| Radiography | 4 | 2016 | 6919 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 18293 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 2 | 2007 | 791 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 4348 | 0.050 |
Why?
|
| Survival | 1 | 2003 | 160 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2018 | 36532 | 0.050 |
Why?
|
| Sheep | 5 | 1989 | 1440 | 0.050 |
Why?
|
| Marital Status | 1 | 2024 | 426 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 2054 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2009 | 1611 | 0.050 |
Why?
|
| Age Distribution | 2 | 2006 | 2858 | 0.050 |
Why?
|
| Phosphoramide Mustards | 2 | 1992 | 18 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2016 | 5020 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 6547 | 0.050 |
Why?
|
| Cardiovascular Diseases | 4 | 2019 | 15652 | 0.050 |
Why?
|
| Toremifene | 1 | 2002 | 26 | 0.050 |
Why?
|
| Communication | 1 | 2016 | 3916 | 0.050 |
Why?
|
| Biomedical Research | 2 | 2009 | 3458 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2011 | 2900 | 0.050 |
Why?
|
| Trypsin Inhibitor, Bowman-Birk Soybean | 1 | 2001 | 3 | 0.050 |
Why?
|
| Adenoma | 1 | 2012 | 2152 | 0.050 |
Why?
|
| Trypsin Inhibitors | 1 | 2001 | 32 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2014 | 3714 | 0.050 |
Why?
|
| Tarsal Bones | 1 | 2002 | 72 | 0.050 |
Why?
|
| Tissue Banks | 1 | 2002 | 183 | 0.050 |
Why?
|
| Breast Neoplasms, Male | 1 | 2003 | 212 | 0.050 |
Why?
|
| Spain | 1 | 2022 | 483 | 0.050 |
Why?
|
| Receptors, Endothelin | 1 | 2001 | 56 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2015 | 1776 | 0.050 |
Why?
|
| Fluorouracil | 2 | 1999 | 1648 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2003 | 663 | 0.050 |
Why?
|
| Nanostructures | 1 | 2006 | 548 | 0.050 |
Why?
|
| Estradiol | 3 | 2008 | 1947 | 0.050 |
Why?
|
| Adrenal Cortex | 1 | 2021 | 134 | 0.050 |
Why?
|
| Urinary Bladder | 4 | 2003 | 1154 | 0.040 |
Why?
|
| Bone Density | 3 | 2007 | 3491 | 0.040 |
Why?
|
| Indoles | 1 | 2009 | 1839 | 0.040 |
Why?
|
| Foot Diseases | 1 | 2002 | 147 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2001 | 4778 | 0.040 |
Why?
|
| Immunoassay | 1 | 2004 | 741 | 0.040 |
Why?
|
| Somatomedins | 1 | 2001 | 177 | 0.040 |
Why?
|
| Flavonoids | 1 | 2004 | 448 | 0.040 |
Why?
|
| Stathmin | 1 | 2020 | 68 | 0.040 |
Why?
|
| Sarcoma | 1 | 2011 | 1802 | 0.040 |
Why?
|
| Arthritis, Infectious | 1 | 1984 | 345 | 0.040 |
Why?
|
| In Situ Hybridization | 3 | 2015 | 1886 | 0.040 |
Why?
|
| Reproductive History | 1 | 2001 | 210 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 3413 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 1993 | 587 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8703 | 0.040 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2000 | 226 | 0.040 |
Why?
|
| Isoenzymes | 2 | 2002 | 1689 | 0.040 |
Why?
|
| Drug Resistance | 5 | 1990 | 1591 | 0.040 |
Why?
|
| Glioblastoma | 1 | 2015 | 3459 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 2194 | 0.040 |
Why?
|
| Actuarial Analysis | 1 | 1999 | 366 | 0.040 |
Why?
|
| Cell Division | 3 | 2009 | 4475 | 0.040 |
Why?
|
| Population Surveillance | 2 | 2008 | 2590 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2002 | 784 | 0.040 |
Why?
|
| Proteins | 1 | 2014 | 5995 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2020 | 301 | 0.040 |
Why?
|
| Hospitalization | 1 | 2019 | 10808 | 0.040 |
Why?
|
| Macaca fascicularis | 5 | 1987 | 907 | 0.040 |
Why?
|
| Linear Models | 1 | 2009 | 5876 | 0.040 |
Why?
|
| Medicare | 2 | 2016 | 6823 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2001 | 416 | 0.040 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 1999 | 78 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7851 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2001 | 594 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2022 | 798 | 0.040 |
Why?
|
| Terminal Repeat Sequences | 1 | 1998 | 70 | 0.040 |
Why?
|
| Hematopoiesis | 2 | 2024 | 2058 | 0.040 |
Why?
|
| Globins | 3 | 1989 | 406 | 0.040 |
Why?
|
| Neomycin | 3 | 1987 | 94 | 0.040 |
Why?
|
| Proteomics | 2 | 2015 | 3910 | 0.040 |
Why?
|
| Recombinant Proteins | 5 | 2014 | 6493 | 0.040 |
Why?
|
| Vaccinia virus | 1 | 2000 | 327 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2018 | 158 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 1998 | 108 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2003 | 1333 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2721 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 967 | 0.040 |
Why?
|
| Neutropenia | 2 | 2012 | 893 | 0.040 |
Why?
|
| Health Planning Guidelines | 2 | 2012 | 151 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 3835 | 0.040 |
Why?
|
| Lysine | 1 | 2022 | 991 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2008 | 3561 | 0.040 |
Why?
|
| Spliceosomes | 1 | 2018 | 116 | 0.040 |
Why?
|
| Decision Making | 2 | 2013 | 3965 | 0.040 |
Why?
|
| Leucovorin | 1 | 1999 | 641 | 0.040 |
Why?
|
| Chorionic Gonadotropin | 2 | 2006 | 457 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2007 | 1510 | 0.040 |
Why?
|
| Homeodomain Proteins | 2 | 2018 | 2428 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 2 | 2004 | 2631 | 0.040 |
Why?
|
| Fatigue | 2 | 2019 | 1549 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 7875 | 0.030 |
Why?
|
| Heredity | 1 | 2017 | 149 | 0.030 |
Why?
|
| Cullin Proteins | 1 | 2018 | 178 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2002 | 866 | 0.030 |
Why?
|
| Gene Deletion | 2 | 2015 | 2666 | 0.030 |
Why?
|
| Europe | 1 | 2024 | 3423 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2005 | 2113 | 0.030 |
Why?
|
| Transduction, Genetic | 3 | 1990 | 898 | 0.030 |
Why?
|
| DNA, Recombinant | 4 | 2000 | 455 | 0.030 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 1998 | 254 | 0.030 |
Why?
|
| Genes | 4 | 1989 | 1825 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2005 | 2446 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2001 | 689 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2005 | 2573 | 0.030 |
Why?
|
| Tropomyosin | 1 | 1996 | 103 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2007 | 2747 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2017 | 2927 | 0.030 |
Why?
|
| RNA Transport | 1 | 2016 | 42 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 1996 | 188 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2020 | 2476 | 0.030 |
Why?
|
| Health Status | 1 | 2009 | 4080 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 5783 | 0.030 |
Why?
|
| Drug Antagonism | 1 | 2015 | 50 | 0.030 |
Why?
|
| Molecular Sequence Data | 7 | 2004 | 17594 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2019 | 4015 | 0.030 |
Why?
|
| Guidelines as Topic | 2 | 2015 | 1394 | 0.030 |
Why?
|
| Ferritins | 1 | 2018 | 600 | 0.030 |
Why?
|
| DNA, Complementary | 3 | 2008 | 1984 | 0.030 |
Why?
|
| Cell Fractionation | 1 | 2016 | 243 | 0.030 |
Why?
|
| Cholestenone 5 alpha-Reductase | 2 | 2009 | 21 | 0.030 |
Why?
|
| Research Personnel | 1 | 2020 | 590 | 0.030 |
Why?
|
| Breast Neoplasms | 5 | 2005 | 21056 | 0.030 |
Why?
|
| Liver | 2 | 2007 | 7562 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 3 | 2015 | 5526 | 0.030 |
Why?
|
| E2F3 Transcription Factor | 1 | 2015 | 36 | 0.030 |
Why?
|
| Sexuality | 1 | 1997 | 180 | 0.030 |
Why?
|
| Aneuploidy | 1 | 2019 | 578 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2013 | 1737 | 0.030 |
Why?
|
| Massachusetts | 4 | 2014 | 8875 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 2844 | 0.030 |
Why?
|
| Piperazines | 1 | 2006 | 2549 | 0.030 |
Why?
|
| Sweden | 2 | 2008 | 1381 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2021 | 2077 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2015 | 191 | 0.030 |
Why?
|
| Thalassemia | 2 | 1986 | 267 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 399 | 0.030 |
Why?
|
| Societies, Medical | 3 | 2012 | 3956 | 0.030 |
Why?
|
| Gene Amplification | 2 | 2015 | 1091 | 0.030 |
Why?
|
| Macaca | 2 | 1987 | 413 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2001 | 754 | 0.030 |
Why?
|
| Health Surveys | 3 | 2013 | 4056 | 0.030 |
Why?
|
| Protein Array Analysis | 2 | 2007 | 399 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2015 | 3586 | 0.030 |
Why?
|
| Affect | 2 | 2019 | 1500 | 0.030 |
Why?
|
| Lymphocele | 1 | 1994 | 19 | 0.030 |
Why?
|
| Citrates | 1 | 1994 | 130 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 2015 | 9071 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2018 | 2266 | 0.030 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2014 | 30 | 0.030 |
Why?
|
| Androsterone | 1 | 2013 | 14 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2019 | 669 | 0.030 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2014 | 134 | 0.030 |
Why?
|
| Filgrastim | 1 | 2014 | 131 | 0.030 |
Why?
|
| Token Economy | 1 | 2013 | 17 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2004 | 2692 | 0.030 |
Why?
|
| Nuclear Receptor Coactivator 3 | 2 | 2005 | 45 | 0.030 |
Why?
|
| Administration, Intravesical | 1 | 1994 | 88 | 0.030 |
Why?
|
| Social Support | 1 | 2024 | 2192 | 0.030 |
Why?
|
| Gynecomastia | 1 | 2014 | 87 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2001 | 6203 | 0.030 |
Why?
|
| Gallium Radioisotopes | 1 | 1994 | 195 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 870 | 0.030 |
Why?
|
| Minority Groups | 1 | 2021 | 1207 | 0.030 |
Why?
|
| Peptides | 1 | 2005 | 4331 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2015 | 299 | 0.030 |
Why?
|
| Histones | 2 | 2017 | 2584 | 0.030 |
Why?
|
| Receptor, erbB-2 | 2 | 2002 | 2593 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2014 | 212 | 0.030 |
Why?
|
| Base Sequence | 7 | 2003 | 12403 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2017 | 604 | 0.030 |
Why?
|
| Organ Size | 2 | 2010 | 2260 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2015 | 375 | 0.030 |
Why?
|
| Digital Rectal Examination | 1 | 2013 | 42 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2019 | 1192 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2011 | 26318 | 0.030 |
Why?
|
| Sensitivity and Specificity | 5 | 2013 | 14652 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2019 | 962 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 240 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 684 | 0.020 |
Why?
|
| Urinary Diversion | 1 | 1993 | 134 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2012 | 339 | 0.020 |
Why?
|
| Indazoles | 1 | 2014 | 303 | 0.020 |
Why?
|
| Homozygote | 1 | 1997 | 1775 | 0.020 |
Why?
|
| Acetylation | 1 | 2014 | 1053 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 1996 | 1077 | 0.020 |
Why?
|
| Genome | 1 | 2020 | 1753 | 0.020 |
Why?
|
| Luciferases | 1 | 2013 | 713 | 0.020 |
Why?
|
| Animals, Genetically Modified | 2 | 1987 | 1560 | 0.020 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2012 | 169 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 640 | 0.020 |
Why?
|
| Hot Flashes | 1 | 2014 | 330 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 1009 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2015 | 796 | 0.020 |
Why?
|
| Pedigree | 2 | 2017 | 4526 | 0.020 |
Why?
|
| Leadership | 1 | 2020 | 1392 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2014 | 1160 | 0.020 |
Why?
|
| Chromosome Breakpoints | 1 | 2011 | 93 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 9550 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 618 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 2796 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2014 | 1679 | 0.020 |
Why?
|
| DNA Transposable Elements | 4 | 1987 | 765 | 0.020 |
Why?
|
| Bleomycin | 1 | 1992 | 491 | 0.020 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 407 | 0.020 |
Why?
|
| DNA Primers | 2 | 2009 | 2825 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2006 | 8067 | 0.020 |
Why?
|
| Urethral Obstruction | 2 | 2003 | 56 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 639 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2014 | 1602 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2018 | 1534 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 2002 | 4165 | 0.020 |
Why?
|
| Methyltransferases | 1 | 2012 | 371 | 0.020 |
Why?
|
| Bone Marrow Cells | 5 | 1990 | 2412 | 0.020 |
Why?
|
| Software | 1 | 2024 | 4462 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2013 | 932 | 0.020 |
Why?
|
| Oxalates | 1 | 1990 | 99 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 6220 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 1624 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2014 | 852 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2018 | 2132 | 0.020 |
Why?
|
| American Cancer Society | 1 | 2009 | 69 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 3925 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2013 | 700 | 0.020 |
Why?
|
| Lymphocytes | 3 | 2002 | 2599 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2014 | 1188 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2016 | 2424 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2014 | 1158 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 703 | 0.020 |
Why?
|
| Uremia | 1 | 1990 | 202 | 0.020 |
Why?
|
| Angiogenic Proteins | 1 | 2009 | 101 | 0.020 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2015 | 954 | 0.020 |
Why?
|
| Recombination, Genetic | 2 | 2011 | 1525 | 0.020 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2009 | 196 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 1406 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2003 | 5089 | 0.020 |
Why?
|
| Government Agencies | 1 | 2009 | 161 | 0.020 |
Why?
|
| Cytokines | 1 | 2003 | 7421 | 0.020 |
Why?
|
| Adolescent | 7 | 2015 | 88835 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2002 | 1546 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2013 | 769 | 0.020 |
Why?
|
| Chemokines | 1 | 2012 | 956 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2010 | 629 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2014 | 687 | 0.020 |
Why?
|
| Adiponectin | 1 | 2013 | 1119 | 0.020 |
Why?
|
| Longevity | 1 | 2015 | 1087 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 1659 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2011 | 614 | 0.020 |
Why?
|
| Propionates | 1 | 2008 | 180 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 207 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 2009 | 4618 | 0.020 |
Why?
|
| Lipids | 1 | 2018 | 3315 | 0.020 |
Why?
|
| Acetaminophen | 1 | 2011 | 547 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 1240 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1748 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2012 | 1144 | 0.020 |
Why?
|
| Health Personnel | 1 | 2000 | 3390 | 0.020 |
Why?
|
| Germ Cells | 1 | 2011 | 647 | 0.020 |
Why?
|
| Deoxyadenosines | 1 | 1986 | 27 | 0.020 |
Why?
|
| Heart Failure | 1 | 2011 | 11840 | 0.020 |
Why?
|
| Binding Sites | 1 | 2015 | 6001 | 0.020 |
Why?
|
| DNA, Circular | 1 | 1987 | 97 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 2627 | 0.020 |
Why?
|
| Physicians | 2 | 2008 | 4588 | 0.020 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2014 | 993 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2014 | 3946 | 0.020 |
Why?
|
| Neuroendocrine Tumors | 1 | 2013 | 654 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 1370 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 416 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2009 | 955 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1994 | 1792 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2008 | 558 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 1987 | 438 | 0.020 |
Why?
|
| Epithelial Cells | 2 | 2010 | 3681 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2007 | 525 | 0.020 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1987 | 168 | 0.020 |
Why?
|
| Polyglactin 910 | 1 | 2006 | 56 | 0.020 |
Why?
|
| Amino Acid Substitution | 2 | 2001 | 1740 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2006 | 226 | 0.020 |
Why?
|
| Consensus | 1 | 2016 | 3202 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 720 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 3750 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7838 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2007 | 344 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 1806 | 0.020 |
Why?
|
| Capsules | 1 | 2006 | 193 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1987 | 1306 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2005 | 155 | 0.020 |
Why?
|
| Leptin | 1 | 2013 | 1596 | 0.020 |
Why?
|
| Heterozygote | 2 | 2004 | 2794 | 0.020 |
Why?
|
| Anopheles | 1 | 1987 | 193 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2010 | 906 | 0.020 |
Why?
|
| DNA | 2 | 1990 | 7202 | 0.020 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 3685 | 0.010 |
Why?
|
| Uterus | 1 | 1989 | 661 | 0.010 |
Why?
|
| Estradiol Congeners | 1 | 2004 | 22 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2014 | 2589 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4260 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2010 | 1187 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1701 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 1612 | 0.010 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 127 | 0.010 |
Why?
|
| Spirochaetales | 1 | 1984 | 26 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 2007 | 558 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2014 | 5379 | 0.010 |
Why?
|
| Phenols | 1 | 2008 | 522 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2005 | 572 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2005 | 696 | 0.010 |
Why?
|
| Sleep | 1 | 2020 | 4813 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2004 | 421 | 0.010 |
Why?
|
| Meningeal Neoplasms | 1 | 1993 | 1252 | 0.010 |
Why?
|
| Leucine | 2 | 1999 | 546 | 0.010 |
Why?
|
| New Jersey | 1 | 2004 | 296 | 0.010 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2003 | 13 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2010 | 3089 | 0.010 |
Why?
|
| Ethinyl Estradiol | 1 | 2004 | 111 | 0.010 |
Why?
|
| Quantitative Trait Loci | 1 | 2012 | 2140 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1987 | 1077 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2005 | 332 | 0.010 |
Why?
|
| Cytogenetics | 1 | 2003 | 198 | 0.010 |
Why?
|
| Bone Remodeling | 1 | 2007 | 577 | 0.010 |
Why?
|
| Protein Binding | 1 | 2015 | 9296 | 0.010 |
Why?
|
| Drug Design | 1 | 2008 | 1042 | 0.010 |
Why?
|
| Macaca mulatta | 2 | 1987 | 2341 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2003 | 101 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 3051 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 3278 | 0.010 |
Why?
|
| Inflammation | 2 | 2013 | 10850 | 0.010 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2003 | 135 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 2865 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2005 | 609 | 0.010 |
Why?
|
| Cognition | 1 | 2020 | 7049 | 0.010 |
Why?
|
| Exoribonucleases | 1 | 2002 | 88 | 0.010 |
Why?
|
| Edema | 1 | 2006 | 760 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2012 | 3449 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2004 | 856 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2007 | 1250 | 0.010 |
Why?
|
| Phosphotransferases | 3 | 1988 | 302 | 0.010 |
Why?
|
| Carotenoids | 1 | 2005 | 619 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 3529 | 0.010 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2002 | 99 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2016 | 3286 | 0.010 |
Why?
|
| Fetus | 2 | 1986 | 1870 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 5501 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 2003 | 420 | 0.010 |
Why?
|
| Folic Acid Antagonists | 1 | 1981 | 75 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2003 | 15747 | 0.010 |
Why?
|
| Codon | 1 | 2003 | 595 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 3850 | 0.010 |
Why?
|
| Young Adult | 3 | 2015 | 59889 | 0.010 |
Why?
|
| Osteocalcin | 1 | 2001 | 271 | 0.010 |
Why?
|
| Boston | 2 | 2007 | 9338 | 0.010 |
Why?
|
| Cell Communication | 1 | 2008 | 1660 | 0.010 |
Why?
|
| Fecal Incontinence | 1 | 2003 | 245 | 0.010 |
Why?
|
| Rhabdomyosarcoma | 1 | 2003 | 354 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 1936 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2015 | 42500 | 0.010 |
Why?
|
| Complementary Therapies | 1 | 2004 | 487 | 0.010 |
Why?
|
| Eligibility Determination | 1 | 2004 | 423 | 0.010 |
Why?
|
| Prevalence | 1 | 1997 | 15842 | 0.010 |
Why?
|
| Transgenes | 1 | 2003 | 1015 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2004 | 13400 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1986 | 2086 | 0.010 |
Why?
|
| Military Personnel | 1 | 2009 | 1252 | 0.010 |
Why?
|
| Debrisoquin | 1 | 1998 | 6 | 0.010 |
Why?
|
| Pelvic Bones | 1 | 2001 | 274 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2007 | 3160 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 2002 | 696 | 0.010 |
Why?
|
| Rats | 2 | 2012 | 23707 | 0.010 |
Why?
|
| Gene Library | 1 | 2001 | 1067 | 0.010 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2002 | 497 | 0.010 |
Why?
|
| Dyspnea | 1 | 2006 | 1352 | 0.010 |
Why?
|
| Calcium, Dietary | 1 | 2001 | 526 | 0.010 |
Why?
|
| Dogs | 3 | 1988 | 3822 | 0.010 |
Why?
|
| Kanamycin Kinase | 2 | 1988 | 34 | 0.010 |
Why?
|
| Valine | 1 | 1999 | 410 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 2108 | 0.010 |
Why?
|
| Testis | 1 | 2001 | 780 | 0.010 |
Why?
|
| Tachycardia | 1 | 2000 | 594 | 0.010 |
Why?
|
| Bone Resorption | 1 | 2001 | 717 | 0.010 |
Why?
|
| Medical Records | 1 | 2003 | 1409 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 2172 | 0.010 |
Why?
|
| Proteome | 1 | 2007 | 1899 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 753 | 0.010 |
Why?
|
| Gentamicins | 2 | 1988 | 244 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 3807 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2001 | 1391 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 1999 | 409 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2001 | 1965 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1987 | 4159 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1991 | 12976 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2006 | 2554 | 0.010 |
Why?
|
| Palliative Care | 2 | 2001 | 3645 | 0.010 |
Why?
|
| Warfarin | 1 | 2004 | 1494 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 2817 | 0.010 |
Why?
|
| Microinjections | 2 | 1987 | 320 | 0.010 |
Why?
|
| Child | 2 | 2015 | 80564 | 0.010 |
Why?
|
| Vaccination | 1 | 2007 | 3426 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 3620 | 0.010 |
Why?
|
| Femur | 1 | 2001 | 1310 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 14751 | 0.010 |
Why?
|
| Hypogonadism | 1 | 2001 | 801 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2007 | 2041 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2014 | 6853 | 0.010 |
Why?
|
| Ifosfamide | 1 | 1995 | 233 | 0.010 |
Why?
|
| Citric Acid | 1 | 1994 | 124 | 0.010 |
Why?
|
| Leukemia | 1 | 2002 | 1522 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2002 | 1874 | 0.010 |
Why?
|
| Research | 1 | 2002 | 1975 | 0.010 |
Why?
|
| Etoposide | 1 | 1995 | 636 | 0.010 |
Why?
|
| Genes, jun | 1 | 1993 | 69 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 36386 | 0.010 |
Why?
|
| Ultrasonography | 2 | 1996 | 5993 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 5302 | 0.010 |
Why?
|
| Fever | 1 | 2000 | 1603 | 0.010 |
Why?
|
| Stem Cells | 1 | 2005 | 3540 | 0.010 |
Why?
|
| Androstenedione | 1 | 1992 | 138 | 0.010 |
Why?
|
| Cecum | 1 | 1993 | 232 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2001 | 1873 | 0.010 |
Why?
|
| Antibodies | 1 | 2000 | 2417 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2004 | 3584 | 0.010 |
Why?
|
| Vitamin D Deficiency | 1 | 2001 | 1348 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 7232 | 0.010 |
Why?
|
| Medicaid | 1 | 2004 | 2833 | 0.010 |
Why?
|
| Harvey murine sarcoma virus | 1 | 1990 | 5 | 0.010 |
Why?
|
| Methylcellulose | 1 | 1990 | 34 | 0.010 |
Why?
|
| Oxalic Acid | 1 | 1990 | 20 | 0.010 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1990 | 80 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 15880 | 0.010 |
Why?
|
| Skin | 1 | 1984 | 4489 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2007 | 4900 | 0.010 |
Why?
|
| Thymidine | 1 | 1990 | 294 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 14448 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1992 | 731 | 0.010 |
Why?
|
| Spleen | 2 | 1986 | 2296 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 1992 | 826 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1990 | 860 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2000 | 3454 | 0.000 |
Why?
|
| Life Style | 1 | 2000 | 3926 | 0.000 |
Why?
|
| Colchicine | 1 | 1990 | 256 | 0.000 |
Why?
|
| Anticoagulants | 1 | 2004 | 4862 | 0.000 |
Why?
|
| Feeding Behavior | 1 | 2000 | 3212 | 0.000 |
Why?
|
| Chelating Agents | 1 | 1990 | 380 | 0.000 |
Why?
|
| DNA, Viral | 2 | 1985 | 2199 | 0.000 |
Why?
|
| Body Weight | 1 | 1999 | 4622 | 0.000 |
Why?
|
| Gastrointestinal Diseases | 1 | 1997 | 1203 | 0.000 |
Why?
|
| Colony-Forming Units Assay | 1 | 1988 | 351 | 0.000 |
Why?
|
| Haplorhini | 1 | 1988 | 520 | 0.000 |
Why?
|
| Leukemia Virus, Murine | 1 | 1987 | 96 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1986 | 297 | 0.000 |
Why?
|
| Pancreatic Elastase | 1 | 1987 | 124 | 0.000 |
Why?
|
| Clone Cells | 1 | 1990 | 1672 | 0.000 |
Why?
|
| Growth Hormone | 1 | 1989 | 566 | 0.000 |
Why?
|
| Genes, Synthetic | 1 | 1987 | 88 | 0.000 |
Why?
|
| Cycloheximide | 1 | 1986 | 339 | 0.000 |
Why?
|
| Reticulocytes | 1 | 1986 | 287 | 0.000 |
Why?
|
| Models, Biological | 1 | 2002 | 9443 | 0.000 |
Why?
|
| Growth Substances | 1 | 1988 | 758 | 0.000 |
Why?
|
| Arteriosclerosis | 1 | 1990 | 1053 | 0.000 |
Why?
|
| Drug Resistance, Microbial | 1 | 1988 | 833 | 0.000 |
Why?
|
| Receptors, Virus | 1 | 1988 | 651 | 0.000 |
Why?
|
| Glycosylation | 1 | 1987 | 1100 | 0.000 |
Why?
|
| Azacitidine | 1 | 1985 | 334 | 0.000 |
Why?
|
| Rabbits | 1 | 1989 | 4734 | 0.000 |
Why?
|
| Selection, Genetic | 1 | 1987 | 878 | 0.000 |
Why?
|
| RNA Splicing | 1 | 1987 | 903 | 0.000 |
Why?
|
| DNA, Bacterial | 1 | 1987 | 1477 | 0.000 |
Why?
|
| Plasmids | 1 | 1987 | 2274 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1987 | 2120 | 0.000 |
Why?
|
| Mice, Mutant Strains | 1 | 1985 | 1745 | 0.000 |
Why?
|
| Fetal Diseases | 1 | 1987 | 914 | 0.000 |
Why?
|
| Aorta | 1 | 1989 | 2028 | 0.000 |
Why?
|
| Models, Chemical | 1 | 1981 | 608 | 0.000 |
Why?
|
| Drosophila melanogaster | 1 | 1987 | 1721 | 0.000 |
Why?
|
| Cell Movement | 1 | 1990 | 5194 | 0.000 |
Why?
|
| Kidney Failure, Chronic | 1 | 1990 | 2495 | 0.000 |
Why?
|
| Calcium | 1 | 1990 | 5767 | 0.000 |
Why?
|
| Graft Survival | 1 | 1987 | 3890 | 0.000 |
Why?
|
| Swine | 1 | 1986 | 5988 | 0.000 |
Why?
|
| Neutrophils | 1 | 1987 | 3776 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1988 | 7478 | 0.000 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1987 | 5753 | 0.000 |
Why?
|
| Pregnancy | 1 | 1987 | 30260 | 0.000 |
Why?
|